BONVENTURE and Ship2B Ventures have invested in the Berlin-based digital health startup ViViRA to expand its innovative app for treating back pain across Germany.
Target Company Overview
ViViRA, a Berlin-based digital health startup, specializes in providing innovative therapy solutions for individuals suffering from back pain. Their flagship product, the ViViRA app, offers a prescription-based digital therapeutic platform designed to facilitate movement therapy at home, thereby addressing musculoskeletal disorders. With a growing number of patients utilizing the application, ViViRA aims to enhance its services by expanding its market reach across Germany and developing additional digital solutions.
According to the Robert Koch Institute, approximately 60% of Germans experience back pain at least once a year, making it a leading cause of work-related disability and premature retirement. The current healthcare provision for back pain patients indicates significant shortcomings, as only 50% of those needing physiotherapy receive the appropriate prescriptions, according to BARMER.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Germany
The digital health sector in Germany is experiencing a significant transformation, especially since the introduction of the Digital Healthcare Act (DVG) in late 2019, which encourages the integration of digital health applications int
Similar Deals
Holland Capital → Semalytix
2025
WMS → ROTOP Pharmaka GmbH
2025
GENUI and SHS Capital → ROTOP Pharmaka GmbH
2025
Great Point Partners → Lyocontract GmbH
2024
ARCHIMED → PlasmidFactory
2023
ARCHIMED → Cube
2023
BONVENTURE, Ship2B Ventures
invested in
ViViRA
in 2024
in a Growth Equity & Expansion Capital deal